Is the psychedelic experience an essential aspect of the therapeutic effect of serotonergic psychedelics? Conceptual, discovery, development and implementation implications for psilocybin and related agents
Expert Opinion on Drug Safety August 28, 2023 DOI: 10.1080/14740338.2023.2253144 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | LSD Psilocybin Serotonin |
| Keywords | Psychotherapist Hallucinogen Pharmacology |
| Citations | 16 |
| Key findings | Psychedelics like psilocybin and LSD show promise as treatments for mood disorders, with FDA breakthrough therapy designation indicating a shift in their regulatory and therapeutic acceptance. |
Abstract
KEYWORDS: Psychedelicpsilocybinlysergic acid diethylamidemood disordersantidepressantsdiscoverypharmacologyFDA
Comparable studies
Other narrative reviews on serotonin, most cited first.
Citations in the library
Cited by 15
- An international Delphi consensus for reporting of setting in psychedelic clinical trials. Nature Medicine June 3, 2025
- A Comprehensive Review of the Current Status of the Cellular Neurobiology of Psychedelics Biology October 28, 2023
- Psychedelics for the Treatment of Psychiatric Disorders: Interpreting and Translating Available Evidence and Guidance for Future Research. American Journal of Psychiatry 2025
- The ketamine chameleon: history, pharmacology, and the contested value of experience. Expert Review of Clinical Pharmacology March 1, 2025
- Non-hallucinogenic psychedelics for mood and anxiety disorders: A systematic review Psychiatry Research May 8, 2025
and 10 more in the library
Cites 30
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine November 3, 2022
- Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation American Journal of Psychiatry March 17, 2021
- A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature 2021
- Psychedelics promote plasticity by directly binding to BDNF receptor TrkB Nature Neuroscience June 1, 2023
and 25 more in the library